Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B H Xu

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|February 20, 2022
[Efficacy and survival outcomes of dose-dense carboplatin plus paclitaxel as neoadjuvant chemotherapy for triple-negative breast cancer]Y Liu, M Xiu, X Wang, et al.
Scientific Reports|September 22, 2016
A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatmentF Du, P Yuan, Z T Zhao, et al.
Scientific Reports|October 15, 2016
Erratum: A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatmentF Du, P Yuan, Z T Zhao, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|February 18, 2021
[Progress on clinical trials of cancer drugs in China, 2020]D W Wu, H Y Huang, Y Tang, et al.
Zhonghua Yi Xue Za Zhi|August 15, 2020
[Phase Ⅲ randomized controlled, multicenter, prospective study of recombinant anti-HER2 humanized monoclonal antibody (Cipterbin) combined with vinorelbine in patients with HER2 positive metastatic breast cancer: the HOPES Study]L Bian, B H Xu, L J Di, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|November 18, 2021
[Correlation between nUGT1A1 gene polymorphisms and adverse events of irinotecan plus S-1 for patients with recurrent or metastatic esophageal squamous cell carcinoma: a prospective, open-label, randomized controlled trial (ESWN 01)]X Wang, Y Liu, J X Huang, et al.
Zhonghua Kou Qiang Yi Xue Za Zhi = Zhonghua Kouqiang Yixue Zazhi = Chinese Journal of Stomatology|April 29, 2022
[Consensus of experts on the oral health management and medical risk prevention for the patients with chronic airway diseases (2022 edition)]Z M Wang, Q Liu, Y X Liu, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|March 22, 2022
[Progress on clinical trials of common gastrointestinal cancer drugs in China from 2012 to 2021]H Y Huang, D W Wu, Q Zhu, et al.
Zhonghua Kou Qiang Yi Xue Za Zhi = Zhonghua Kouqiang Yixue Zazhi = Chinese Journal of Stomatology|April 29, 2022
[Consensus of experts on the medical risk prevention for the patients with cardiovascular diseases during dental treatment (2022 edition)]J Zhang, G H Su, X D Zhang, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|March 6, 2020
[Progress on clinical trials of cancer drugs in China, 2019]H Y Huang, D W Wu, H X Wang, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|February 20, 2022
[Efficacy and survival outcomes of dose-dense carboplatin plus paclitaxel as neoadjuvant chemotherapy for triple-negative breast cancer]Y Liu, M Xiu, X Wang, et al.
Scientific Reports|September 22, 2016
A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatmentF Du, P Yuan, Z T Zhao, et al.
Scientific Reports|October 15, 2016
Erratum: A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatmentF Du, P Yuan, Z T Zhao, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|February 18, 2021
[Progress on clinical trials of cancer drugs in China, 2020]D W Wu, H Y Huang, Y Tang, et al.
Zhonghua Yi Xue Za Zhi|August 15, 2020
[Phase Ⅲ randomized controlled, multicenter, prospective study of recombinant anti-HER2 humanized monoclonal antibody (Cipterbin) combined with vinorelbine in patients with HER2 positive metastatic breast cancer: the HOPES Study]L Bian, B H Xu, L J Di, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|November 18, 2021
[Correlation between nUGT1A1 gene polymorphisms and adverse events of irinotecan plus S-1 for patients with recurrent or metastatic esophageal squamous cell carcinoma: a prospective, open-label, randomized controlled trial (ESWN 01)]X Wang, Y Liu, J X Huang, et al.
Zhonghua Kou Qiang Yi Xue Za Zhi = Zhonghua Kouqiang Yixue Zazhi = Chinese Journal of Stomatology|April 29, 2022
[Consensus of experts on the oral health management and medical risk prevention for the patients with chronic airway diseases (2022 edition)]Z M Wang, Q Liu, Y X Liu, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|March 22, 2022
[Progress on clinical trials of common gastrointestinal cancer drugs in China from 2012 to 2021]H Y Huang, D W Wu, Q Zhu, et al.
Zhonghua Kou Qiang Yi Xue Za Zhi = Zhonghua Kouqiang Yixue Zazhi = Chinese Journal of Stomatology|April 29, 2022
[Consensus of experts on the medical risk prevention for the patients with cardiovascular diseases during dental treatment (2022 edition)]J Zhang, G H Su, X D Zhang, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|March 6, 2020
[Progress on clinical trials of cancer drugs in China, 2019]H Y Huang, D W Wu, H X Wang, et al.
Pageof 7